1312 Stock Overview
An investment holding company, engages in the manufacture and sale of prescription drugs in Mainland China, Singapore, Taiwan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kontafarma China Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.03 |
| 52 Week High | HK$0.048 |
| 52 Week Low | HK$0.026 |
| Beta | 0.031 |
| 11 Month Change | -18.92% |
| 3 Month Change | -9.09% |
| 1 Year Change | -11.76% |
| 33 Year Change | -50.00% |
| 5 Year Change | -83.33% |
| Change since IPO | -86.24% |
Recent News & Updates
Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Oct 09
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?
Sep 04Recent updates
Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Oct 09Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?
Sep 04Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns
May 31There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise
May 24Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?
Dec 28Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Sep 01Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Dec 29Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?
Sep 15Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?
Apr 20Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?
Nov 04Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares
Feb 18These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively
Dec 07Shareholder Returns
| 1312 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -3.2% | 0.07% | -0.6% |
| 1Y | -11.8% | -10.2% | 9.6% |
Return vs Industry: 1312 underperformed the Hong Kong Pharmaceuticals industry which returned -10.2% over the past year.
Return vs Market: 1312 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 1312 volatility | |
|---|---|
| 1312 Average Weekly Movement | 12.5% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.2% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1312 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1312's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 717 | Feifei Wang | www.kontafarma.com.hk |
Kontafarma China Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs in Mainland China, Singapore, Taiwan, and internationally. It operates in Pharmaceutical Business and Fitness Business segments. The company offers chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers; operates in the franchise business; and provides consultation services for fitness and health activities.
Kontafarma China Holdings Limited Fundamentals Summary
| 1312 fundamental statistics | |
|---|---|
| Market cap | HK$167.66m |
| Earnings (TTM) | -HK$63.24m |
| Revenue (TTM) | HK$836.92m |
0.2x
P/S Ratio-2.7x
P/E RatioIs 1312 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1312 income statement (TTM) | |
|---|---|
| Revenue | HK$836.92m |
| Cost of Revenue | HK$335.76m |
| Gross Profit | HK$501.16m |
| Other Expenses | HK$564.40m |
| Earnings | -HK$63.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 59.88% |
| Net Profit Margin | -7.56% |
| Debt/Equity Ratio | 4.1% |
How did 1312 perform over the long term?
See historical performance and comparison